Faron Total Stockholder Equity vs Common Stock Shares Outstanding Analysis

FARN Stock

208.00 2.00 0.95%

Faron Pharmaceuticals financial indicator trend analysis is much more than just examining Faron Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Faron Pharmaceuticals is a good investment. Please check the relationship between Faron Pharmaceuticals Total Stockholder Equity and its Common Stock Shares Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Stockholder Equity vs Common Stock Shares Outstanding

Total Stockholder Equity vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Faron Pharmaceuticals Total Stockholder Equity account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Faron Pharmaceuticals' Total Stockholder Equity and Common Stock Shares Outstanding is -0.69. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Faron Pharmaceuticals Oy, assuming nothing else is changed. The correlation between historical values of Faron Pharmaceuticals' Total Stockholder Equity and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Faron Pharmaceuticals Oy are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Total Stockholder Equity i.e., Faron Pharmaceuticals' Total Stockholder Equity and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.69

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Faron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 10.5 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 20.5 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	1.4M	2.2M	2.5M	2.6M
Depreciation And Amortization	300K	197K	226.6K	185.2K

Interest Expense Depreciation And Amortization

Faron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Long Term Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Short Long Term Debt	Cash	Cash And Short Term Investments
Total Assets		0.25	0.71	0.48	0.2	0.41	-0.48	-0.45	0.42	0.29	0.28	0.67	0.69	0.41	0.28	0.79	0.37	0.4	1.0	0.05	-0.41	0.76	0.25	-0.28	0.98	0.98
Short Long Term Debt Total	0.25		0.27	0.91	-0.86	0.7	0.71	-0.85	0.92	0.63	0.99	0.16	0.25	0.78	0.99	0.19	0.91	0.97	0.23	0.92	0.14	0.4	-0.83	0.78	0.2	0.2
Other Current Liab	0.71	0.27		0.55	-0.09	0.7	-0.2	-0.62	0.42	0.46	0.32	0.82	0.57	0.54	0.33	0.89	0.43	0.47	0.69	0.1	-0.58	0.78	-0.05	-0.25	0.61	0.61
Total Current Liabilities	0.48	0.91	0.55		-0.73	0.84	0.48	-0.92	0.99	0.65	0.9	0.48	0.42	0.82	0.9	0.48	0.94	0.98	0.46	0.83	-0.22	0.63	-0.66	0.58	0.4	0.4
Total Stockholder Equity	0.2	-0.86	-0.09	-0.73		-0.62	-0.93	0.73	-0.75	-0.55	-0.85	0.01	0.06	-0.69	-0.86	0.07	-0.77	-0.8	0.22	-0.87	-0.21	-0.13	0.99	-0.84	0.25	0.25
Current Deferred Revenue	0.41	0.7	0.7	0.84	-0.62		0.37	-0.92	0.78	0.43	0.71	0.59	0.32	0.84	0.73	0.62	0.79	0.81	0.4	0.53	-0.37	0.55	-0.58	0.29	0.31	0.31
Net Debt	-0.48	0.71	-0.2	0.48	-0.93	0.37		-0.48	0.52	0.39	0.7	-0.28	-0.29	0.46	0.7	-0.34	0.53	0.59	-0.51	0.78	0.42	-0.18	-0.95	0.88	-0.54	-0.54
Retained Earnings	-0.45	-0.85	-0.62	-0.92	0.73	-0.92	-0.48		-0.88	-0.55	-0.86	-0.46	-0.38	-0.92	-0.87	-0.57	-0.87	-0.92	-0.43	-0.71	0.15	-0.64	0.69	-0.44	-0.36	-0.36
Accounts Payable	0.42	0.92	0.42	0.99	-0.75	0.78	0.52	-0.88		0.61	0.9	0.39	0.37	0.79	0.9	0.37	0.95	0.97	0.4	0.87	-0.17	0.58	-0.69	0.64	0.35	0.35
Non Current Assets Total	0.29	0.63	0.46	0.65	-0.55	0.43	0.39	-0.55	0.61		0.65	0.45	0.21	0.55	0.63	0.33	0.55	0.66	0.25	0.56	-0.12	0.39	-0.52	0.43	0.22	0.22
Long Term Debt	0.28	0.99	0.32	0.9	-0.85	0.71	0.7	-0.86	0.9	0.65		0.18	0.26	0.79	1.0	0.22	0.9	0.97	0.25	0.89	0.14	0.43	-0.83	0.73	0.22	0.22
Net Receivables	0.67	0.16	0.82	0.48	0.01	0.59	-0.28	-0.46	0.39	0.45	0.18		0.19	0.4	0.19	0.82	0.34	0.36	0.66	-0.01	-0.75	0.55	0.06	-0.27	0.58	0.58
Common Stock Total Equity	0.69	0.25	0.57	0.42	0.06	0.32	-0.29	-0.38	0.37	0.21	0.26	0.19		0.31	0.27	0.47	0.39	0.36	0.69	0.18	-0.23	0.79	0.13	-0.13	0.69	0.69
Common Stock Shares Outstanding	0.41	0.78	0.54	0.82	-0.69	0.84	0.46	-0.92	0.79	0.55	0.79	0.4	0.31		0.8	0.49	0.78	0.83	0.39	0.64	-0.02	0.55	-0.65	0.41	0.34	0.34
Non Current Liabilities Total	0.28	0.99	0.33	0.9	-0.86	0.73	0.7	-0.87	0.9	0.63	1.0	0.19	0.27	0.8		0.24	0.91	0.97	0.26	0.89	0.12	0.44	-0.83	0.72	0.22	0.22
Other Current Assets	0.79	0.19	0.89	0.48	0.07	0.62	-0.34	-0.57	0.37	0.33	0.22	0.82	0.47	0.49	0.24		0.31	0.38	0.79	-0.02	-0.59	0.69	0.12	-0.35	0.69	0.69
Other Stockholder Equity	0.37	0.91	0.43	0.94	-0.77	0.79	0.53	-0.87	0.95	0.55	0.9	0.34	0.39	0.78	0.91	0.31		0.95	0.35	0.8	-0.2	0.58	-0.72	0.57	0.33	0.33
Total Liab	0.4	0.97	0.47	0.98	-0.8	0.81	0.59	-0.92	0.97	0.66	0.97	0.36	0.36	0.83	0.97	0.38	0.95		0.38	0.88	-0.07	0.56	-0.75	0.66	0.33	0.33
Total Current Assets	1.0	0.23	0.69	0.46	0.22	0.4	-0.51	-0.43	0.4	0.25	0.25	0.66	0.69	0.39	0.26	0.79	0.35	0.38		0.03	-0.41	0.76	0.28	-0.3	0.98	0.98
Short Term Debt	0.05	0.92	0.1	0.83	-0.87	0.53	0.78	-0.71	0.87	0.56	0.89	-0.01	0.18	0.64	0.89	-0.02	0.8	0.88	0.03		0.24	0.31	-0.82	0.9	0.0	0.0
Intangible Assets	-0.41	0.14	-0.58	-0.22	-0.21	-0.37	0.42	0.15	-0.17	-0.12	0.14	-0.75	-0.23	-0.02	0.12	-0.59	-0.2	-0.07	-0.41	0.24		-0.4	-0.27	0.43	-0.36	-0.36
Common Stock	0.76	0.4	0.78	0.63	-0.13	0.55	-0.18	-0.64	0.58	0.39	0.43	0.55	0.79	0.55	0.44	0.69	0.58	0.56	0.76	0.31	-0.4		-0.07	-0.11	0.72	0.72
Net Tangible Assets	0.25	-0.83	-0.05	-0.66	0.99	-0.58	-0.95	0.69	-0.69	-0.52	-0.83	0.06	0.13	-0.65	-0.83	0.12	-0.72	-0.75	0.28	-0.82	-0.27	-0.07		-0.81	0.31	0.31
Short Long Term Debt	-0.28	0.78	-0.25	0.58	-0.84	0.29	0.88	-0.44	0.64	0.43	0.73	-0.27	-0.13	0.41	0.72	-0.35	0.57	0.66	-0.3	0.9	0.43	-0.11	-0.81		-0.32	-0.32
Cash	0.98	0.2	0.61	0.4	0.25	0.31	-0.54	-0.36	0.35	0.22	0.22	0.58	0.69	0.34	0.22	0.69	0.33	0.33	0.98	0.0	-0.36	0.72	0.31	-0.32		1.0
Cash And Short Term Investments	0.98	0.2	0.61	0.4	0.25	0.31	-0.54	-0.36	0.35	0.22	0.22	0.58	0.69	0.34	0.22	0.69	0.33	0.33	0.98	0.0	-0.36	0.72	0.31	-0.32	1.0

Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	8.4M	13.2M	11.3M	10.2M	11.8M	10.5M
Short Long Term Debt Total	3.2M	3.5M	13.3M	13.1M	15.1M	15.8M
Other Current Liab	4.1M	4.3M	3.3M	2.4M	2.8M	2.7M
Total Current Liabilities	6.5M	7.2M	10.5M	15.0M	17.3M	18.1M
Total Stockholder Equity	(1.8M)	2.9M	(11.5M)	(15.2M)	(13.6M)	(13.0M)
Net Debt	(883K)	(3.3M)	6.3M	6.2M	7.2M	7.5M
Retained Earnings	(96.6M)	(116.3M)	(143.7M)	(172.2M)	(155.0M)	(147.2M)
Accounts Payable	2.1M	2.2M	5.1M	9.0M	10.3M	10.8M
Non Current Assets Total	996K	1.2M	1.5M	1.4M	1.6M	1.3M
Long Term Debt	2.7M	2.9M	11.1M	9.4M	10.8M	11.4M
Net Receivables	1.3M	1.3M	1.4M	905K	1.0M	981.9K
Common Stock Shares Outstanding	46.8K	51.8K	60.1K	68.8K	79.1K	40.5K
Liabilities And Stockholders Equity	8.4M	13.2M	11.3M	10.2M	11.8M	10.5M
Non Current Liabilities Total	3.7M	3.1M	12.3M	10.4M	11.9M	12.5M
Other Current Assets	3.3M	5.2M	2.7M	2.0M	2.3M	2.5M
Other Stockholder Equity	91.9M	(1K)	129.4M	154.2M	177.3M	186.2M
Total Liab	10.2M	10.3M	22.7M	25.4M	29.2M	30.6M
Total Current Assets	7.4M	12.0M	9.7M	8.9M	10.2M	9.2M
Accumulated Other Comprehensive Income	92.0K	116.5K	129.5K	154.4K	177.5K	186.4K
Intangible Assets	565K	899K	1.2M	1.1M	979.2K	691.5K
Net Tangible Assets	1.1M	(2.4M)	2.0M	(12.6M)	(11.4M)	(10.8M)
Short Long Term Debt	122K	429K	1.9M	3.5M	4.0M	4.2M
Cash	4.1M	6.9M	7.0M	6.9M	6.2M	5.4M
Cash And Short Term Investments	4.1M	6.9M	7.0M	6.9M	6.2M	5.4M
Property Plant And Equipment Net	375K	207K	327K	204K	234.6K	195.6K
Property Plant And Equipment Gross	375K	207K	327K	225K	258.8K	198.1K
Property Plant Equipment	399K	375K	207K	327K	376.1K	192.0K
Non Currrent Assets Other	77K	56K	53K	60K	54K	51.3K
Net Invested Capital	1.0M	6.3M	1.5M	(2.3M)	(2.0M)	(1.9M)
Net Working Capital	868K	4.8M	(741K)	(6.1M)	(5.5M)	(5.3M)
Capital Lease Obligations	375K	200K	316K	213K	191.7K	240K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Faron Total Stockholder Equity vs Common Stock Shares Outstanding Analysis

Total Stockholder Equity vs Common Stock Shares Outstanding

Total Stockholder Equity vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Common Stock Shares Outstanding

Faron Pharmaceuticals fundamental ratios Correlations

Faron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Faron Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Faron Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Long Term Debt
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Accounts Payable	+ 0.99	Total Current Liabilities

Net Tangible Assets	- 0.95	Net Debt
Net Debt	- 0.93	Total Stockholder Equity
Total Liab	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Current Deferred Revenue
Retained Earnings	- 0.92	Total Current Liabilities